Upcoming Biomarkers Events

Biomarkers UK: In-Person

03 - 04 May 2022 |

London, UK

03 - 04 May 2022

London, UK

+ Digital Day: 05 May 2022

Europe’s flagship event for Biomarker Research Returns: the must-attend forum to engage with the latest trends transforming biomarker and translational research

Biomarker Analysis: Online

13 September 2022 |

Online: EDT (UTC-4)

13 September 2022

Online: EDT (UTC-4)

Biomarkers US: In-Person

03 - 04 October 2022 |

San Diego, USA

03 - 04 October 2022

San Diego, USA

+ Digital Day: 05 October 2022 | Online

Gain a US perspective on the latest technologies and novel biomarkers driving forward translational research and precision medicine

Clinical and Translational Biomarkers: Online

03 November 2022 |

Online: GMT (UTC+0)

03 November 2022

Online: GMT (UTC+0)

Biomarkers for NASH Symposium

07 December 2022 |

Online: GMT (UTC+0)

07 December 2022

Online: GMT (UTC+0)

Designed to deliver the latest insights on advancing NASH therapeutic development and diagnosis through non-invasive biomarker strategies

Upcoming Discussion Groups

Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing translational research & biomarker development today.

Register below to receive a live stream of the discussion as well a complimentary report outlining the key findings and conclusions covered.

ctDNA As A Biomarker For Targeted Immunotherapies 

Taking place February 7th 2022 | 4pm GMT (11am EST)

Viewer Registration Coming Soon

Using Biomarkers For Clinical Development & Regulatory Approval

Taking place February 14th 2022 | 3pm GMT (10am EST)

Discussion Topics: 

  • Presentation: “Biomarkers For Clinical Development & Regulatory Approval: Case Study” by Alessandra Di Bacco, Sr. Director – Global Program Leader, Microbiome, at Takeda
  • How biomarkers may inform a meaningful clinical decision for a specific patient 
  • Clinical, statistical and regulatory issues in the use of biomarkers as clinical endpoints 


Discussion Leaders:

  • Alessandra Di Bacco, Senior Director – Global Program Leader, Microbiome, Takeda
  • Deepti Aurora-Garg, Executive Director Companion DiagnosticsMerck

>Register HERE

Utilizing Real-World Evidence for Drug Development   

Taking place March 28th 2022

Viewer Registration Coming Soon

Fluid Biomarkers for Neurodegenerative Disease  

Taking place April 14th 2022 | 3pm GMT (10am EST)

Discussion Topics:

  • Presentation: “Case Study”, by Jordi Clarimon, Head of Fluid Biomarkers, Lundbeck 
  • Novel fluid biomarkers for neurodegenerative diseases development and diagnosis 
  • Challenges of the field & how they could be overcome with new methodological advances 


>Register (free) HERE

Spatial Biomarkers & Multiplexed Immunofluorescence in Immuno-oncology   

Taking place May 23rd 2022

Viewer Registration Coming Soon

Current Status of Omics-based Biomarkers 

Taking place June 24th 2022 | 3pm GMT (10am EST)

Discussion Topics:

  • Presentation: “The Intersection between Spatial and Drug Discovery”, by Anna Lyubetskaya, Principal Scientist, BMS 
  • Spatial heterogeneity and the application of spatial technology to biomarkers 
  • Advances in high-throughput ‘omics’ technologies to accelerate the pace of biomarker discovery 
  • Comprehensive molecular profiling for improved diagnostics and therapeutics 
  • Limitations of different omics platforms 


>Register now HERE 

Reports and write-ups pertaining to previous Discussion Groups are available in our In-Depth section.

Previous Discussion Groups

December 2021

Flow cytometry is a powerful quantitative and preparative tool, allowing for the analytical interrogation of single cells amongst potentially millions of cells in minutes. Since its inception in 1953 and commercial popularisation in the 1970s, flow cytometry has emerged as a leading and sophisticated technology in applying the high-resolution characterisation of single cells within complex cellular networks. Challenges remain, however, and in our first biomarkers discussion group we bring together an exclusive panel of key opinion leaders to discuss the key factors behind the market’s growth, priorities, future outlook & challenges.

Discussion Points:

  • Validating flow cytometry techniques 
  • Developing high-throughput approaches & improving robustness 
  • Data management strategies, including informatics, sample delivery & AI/ML approaches 
  • Multiplexed high-throughput flow cytometry for drug discovery & repurposing 
  • Regulatory perspectives on the various barriers/challenges of flow-based testing  

Discussion Group Leaders:

  • Larry A. Sklar,
    Distinguished Professor Emeritus, University of New Mexico
  • Maria Hernandez-Fuentes,
    Head of Huma Tissue Technologies, UCB

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Biomarkers